Online inquiry

IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4756MR)

This product GTTS-WQ4756MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Osteogenesis imperfecta (OI) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4756MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8955MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ6706MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ299MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ14880MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ1704MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ9493MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ8066MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ1873MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN1884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW